Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNC1 | P48547 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832754 | 0.72 | ALDH1A1 (0.39) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| SCHEMBL30984256 | 0.70 | KCNA3 (0.38) | KCNC1KDM4EALDH1A1KCNA3HSD17B10 | |
| SCHEMBL31266865 | 0.70 | KCNA3 (0.38) | KCNC1KDM4EALDH1A1KCNA3HSD17B10 | |
| SCHEMBL31426140 | 0.67 | L3MBTL1 (0.44) | KDM4EALDH1A1GAAGLAKCNA3 | |
| SCHEMBL25056111 | 0.66 | KDM4E (0.41) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| SCHEMBL27610033 | 0.65 | ALDH1A1 (0.46) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| SCHEMBL27033003 | 0.64 | CA12 (0.52) | KDM4EKCNA3HSD17B10LMNATSHR | |
| SCHEMBL17221702 | 0.64 | CYP1A1 (0.41) | KDM4EALDH1A1KCNA3HSD17B10HPGD | |
| SCHEMBL436444 | 0.64 | KDM4E (0.42) | KDM4EALDH1A1KMT2ARAB9AMAPT | |
| SCHEMBL8325905 | 0.64 | L3MBTL1 (0.46) | KDM4EALDH1A1GAAGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2705030-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | KCNC1 4480/4885KDM4E 1635/4885ALDH1A1 312/4885 |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | CES2, DNPEP, METAP2 | KCNC1 2931/4885KDM4E 1272/4885ALDH1A1 855/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | KCNC1 4480/4885KDM4E 1635/4885ALDH1A1 312/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | KCNC1 3427/4885KDM4E 1321/4885ALDH1A1 1755/4885 |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | DNPEP, CES2, AADAC | KCNC1 3427/4885KDM4E 1321/4885ALDH1A1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.